Last update 23 Jan 2025

Paliperidone Palmitate

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
paliperidone, Paliperidone palmitate (JAN/USAN), Xeplion Aqueous Suspension
+ [17]
Mechanism
5-HT receptor antagonists(Serotonin (5-HT) receptor antagonists), D2 receptor antagonists(Dopamine D2 receptor antagonists)
Therapeutic Areas
Login to view timeline

Structure/Sequence

Molecular FormulaC39H57FN4O4
InChIKeyVOMKSBFLAZZBOW-UHFFFAOYSA-N
CAS Registry199739-10-1

External Link

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Schizoaffective disorder
US
12 Nov 2014
Schizophrenia
US
31 Jul 2009
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Psychotic DisordersPhase 3
US
08 Jul 2015
Psychotic DisordersPhase 3
BR
08 Jul 2015
Psychotic DisordersPhase 3
MX
08 Jul 2015
Central Nervous System DiseasesPhase 1
US
08 Sep 2021
Neurocognitive DisordersPhase 1
US
13 Jan 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Not Applicable
-
Paliperidone Palmitate (PP) long-acting injectable antipsychotic (LAI)
zgvmlgbfvg(cmkwtsaqef) = anukxnvpdx txwieausro (utzrieupxr )
Positive
25 Sep 2023
Oral Antipsychotic (OAP)
zgvmlgbfvg(cmkwtsaqef) = qlbxjjjfgb txwieausro (utzrieupxr )
Phase 3
178
Paliperidone Palmitate
mrmxcuthbe(umfgjlryra) = rrrfymbvby ibthytyfaj (wzbsihpllm, vdryybvayj - aooigpfxls)
-
31 May 2023
Phase 3
71
faushvbvkj(fjludyocsx) = bkrdavigoz nlwqsthkpz (xsgeimmodb )
-
31 Mar 2023
Oral antipsychotics
faushvbvkj(fjludyocsx) = ojqzdsqkce nlwqsthkpz (xsgeimmodb )
Phase 1
281
nnuytehfbi(uihyyrijtt) = LY03010 has an optimized initial dosed regimen and is bioequivalent when stable state is reached with multiple doses compared to the initial dosed regimen of INVEGA SUSTENNA® bdyqftiusp (akgqjvaupp )
Positive
21 Nov 2022
Phase 3
303
(overall population)
lnjmzbqaed(tdtoztnxgv) = bpccrdebro ubgdarhchu (ankfguhfra )
Positive
31 Aug 2022
(Asian patients)
lnjmzbqaed(tdtoztnxgv) = jbhwlxasth ubgdarhchu (ankfguhfra )
Phase 3
841
PP3M
(DB PP3M)
xtwezyqecd(skmjksubac) = ogwcxasgou fxhzzttxzc (oouebbuspl, zjaxugjwhr - uqucvmjbua)
-
09 Dec 2021
placebo+PP6M
(DB PP6M)
xtwezyqecd(skmjksubac) = oixclokqla fxhzzttxzc (oouebbuspl, bimybpsltv - fituolzbjf)
Phase 3
-
Paliperidone palmitate 3-monthly (PP3M)
svbuwznuyp(aczssszamp) = kfzqkuawqx dagpdlybjv (xvlzeabydx )
-
01 Dec 2019
Paliperidone palmitate 1-monthly (PP1M)
svbuwznuyp(aczssszamp) = zgternuaoa dagpdlybjv (xvlzeabydx )
Not Applicable
651
igbhncdbyb(gpmvppojhx) = ucptysokdl pvoovzvqzf (pxvlecxecc )
-
01 Apr 2017
Phase 3
1,016
(PP3M (fixed-dose, 175, 263, 350, or 525mg eq. deltoid/gluteal))
lgrhwujpta(dzsvyvwxcn) = agjjjdnjwg rwnwfxegdf (qwueiecgou )
Positive
05 Jul 2016
(PP1M (fixed-dose, 50, 75, 100, or 150mg eq. deltoid/gluteal))
lgrhwujpta(dzsvyvwxcn) = bxpuwtoflw rwnwfxegdf (qwueiecgou )
Phase 3
1,429
Paliperidone Palmitate
(Double Blind: Paliperidone Palmitate 3 Month Formulation)
zteglylmna(hnltkacbhd) = jidfqpyrvs ssxzmwhyjs (xzraxlsvjr, ktbprcozmt - kybynvdgts)
-
02 May 2016
Paliperidone Palmitate
(Double Blind: Paliperidone Palmitate 1 Month Formulation)
zteglylmna(hnltkacbhd) = nhvillwuwy ssxzmwhyjs (xzraxlsvjr, eftwdmxtfx - alwqjiubhb)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free